Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 5/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | KRAS | P01116 | 6/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599828 | 0.93 | TYMP (0.49) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL16401878 | 0.89 | TYMP (0.49) | TYMPTAAR1HPGDHINT1GSK3A | |
| SCHEMBL6231869 | 0.87 | TAAR1 (0.41) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL10446715 | 0.86 | TYMP (0.44) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL6234136 | 0.85 | TAAR1 (0.39) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL2108532 | 0.85 | TYMP (0.54) | TYMPTAAR1HPGDHINT1GSK3A | |
| SCHEMBL16242934 | 0.84 | TAAR1 (0.40) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL9320640 | 0.84 | TAAR1 (0.44) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL16401489 | 0.84 | TYMP (0.48) | TYMPTAAR1HPGDHINT1TAS1R3 | |
| SCHEMBL2107702 | 0.84 | TYMP (0.44) | TYMPTAAR1HPGDHINT1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | TYMP 1/4885TAAR1 4605/4885HPGD 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.